Get Started in Minutes
How Cuvitru Copay Assistance Works
1 – Check Your Coverage/Benefits Verification
Our team of expert billers finds the best avenues of coverage that minimize out-of-pocket costs.
2 – Transfer Prescription to AmeriPharma
We process your prescription by working with your previous pharmacy or prescriber, making the transition quick and easy.
3 – Prior Authorization
Our team of specialists obtains approval from your insurance companies within 24 to 72 hours.
4 – Copay Assistance & Financial Aid
We secure financial aid and decrease copays, out-of-pocket expenses, and high deductibles. To date, AmeriPharma Specialty Care has secured $55 million in financial assistance for our patients.
5 – Nursing Care Coordination
AmeriPharma puts your schedule and home environment first when scheduling and coordinating one of our specialized nurses for your in-home infusions.
6 – Delivery Coordination
Medications are always delivered in strict compliance with the specific requirements for immune globulin shipping. Next-day and overnight cold-chain deliveries are coordinated around your schedule.
What Is Cuvitru?
Cuvitru (generic name: immune globulin) is derived from human plasma, and it is given to patients with antibody deficiencies to protect against infections.
This medicine belongs to the immune globulins drug class. Cuvitru is FDA approved to be used as a monotherapy or adjunct therapy with other medications.
Cuvitru is an immunoglobulin solution that is administered via subcutaneous infusion only. It works by replacing antibodies that are not functioning properly or not present in the human body to help fight off infections. FDA-approved doses are given to increase extremely low blood immunoglobulin levels to required levels.
What Is Cuvitru Used To Treat?
Cuvitru is Indicated for:
- Primary Humoral Immunodeficiency (PI) in adults and pediatric patients 2 years and older (people with inborn lack of antibody generation).
- Blood cancer patients with little antibody production and recurring infections when preventative antibiotics can not be used.
- Bone marrow cancer patients and those who lack antibody production with repeated infections.
- Decreased levels of antibodies following transplantation of bone marrow cells from another patient.
Blood Clot Risk Factors
Cuvitru has a Black Box Warning due to the possibility of causing blood clots.
Patients are at increased risk of having blood clots if they have one or more of the following risk factors:
- Advanced age
- Sedentary lifestyle
- Hypercoagulable conditions
- History of previous blood clots
- Estrogen use
There may be other factors, and patients are encouraged to discuss them with their doctor.
To help prevent or reduce the risk of blood clots, the manufacturer recommends infusing at the minimum dose and lowest infusion rate possible. Monitor signs and symptoms during and after the treatment.
Copay and Financial Assistance
AmeriPharma Specialty Care alleviates financial burdens for patients and their families
Advanced software locates funding sources to match you with top-dollar foundation programs
One of our copay assistance specialists will assist with the application process
Automatic updates will be sent to you and your physician on the status of the funding
Cuvitru Side Effects
Allergic reaction symptoms:
- Red and swollen skin
- Shortness of breath
- Chest tightness
- Trouble breathing
- Swelling of face and lips
Symptoms requiring urgent medical attention:
- Sore throat
- Abnormal heart rate
- Mood swings
- Speech abnormalities
- Increased sweating
- Vision abnormalities
- Belly pain
- Dark urine
- Yellow skin or eyes
- Difficulty passing urine
- Blood in urine
- Frequent urination
- Weight gain
Elevated or decreased blood pressure:
- Blurred vision
Respiratory infections and inflammation:
- Asthma bronchitis
Injection site reactions:
- Redness of the skin
- Mild discomfort
Cuvitru is administered under the skin (subcutaneously), typically by a trained healthcare professional.
Dosing varies from patient to patient.
Factors That Influence Dosing Calculations:
- Body weight
- Blood IgG levels
- Medical history
- Current conditions
- Clinical response to the treatment
Based on these factors, the patient (a child or adult) may be prescribed a loading dose of at least 1.0-2.5 ml/kg of body weight divided over a few consecutive days.
Following this loading dose, patients will start to receive Cuvitru at regular intervals from daily to once every two weeks.
The total monthly dose will be between 1.5-5.0 ml/kg of body weight after the loading dose.
The doctor may adjust the dose over time to achieve the desired clinical response and serum IgG levels.
For patients who are switching from another IVIG brand, the Cuvitru dose will be based on the previous IVIG dose and will be adjusted according to the number and frequency of infusion.
It is not recommended to make changes to the dose or dosing interval without talking to the doctor.
If you miss a dose, it is important to speak to the doctor as early as possible and get a new dosing schedule. Avoid doubling the dose to catch up.